Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B. D’Agostino, et al.
Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease.
N Engl J Med, 346 (2002), pp. 476-483
[2.]
S.H. Mudd, J.D. Finkelstein, H. Refsum, P.M. Veland, M.R. Malinow, S.R. Lentz, et al.
Homocysteine and its disulfide derivatives. A suggested consensus terminology.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1704-1706
[3.]
F. Blanco-Vaca, R. Areclús, F. González-Sastre, J. Ordóñez-Llanos, J.M. Queraltó-Compañó.
Comparison of the abbott imx® and a high-performance chromatography method for measuring total plasma homocysteine.
Clin Chem Lab Med, 38 (2000), pp. 327-329
[4.]
F. Blanco-Vaca, R. Deulofeu, M.A. Vilaseca, P. Chacón, E. Dulin.
Determinación de homocisteína en plasma: metabolismo, metodología, interpretación de resultados y papel en la evaluación del riesgo cardiovascular.
Química Clínica, 21 (2002), pp. 243-250
[5.]
J.W. Eikelboom, E. Lonn, J. Genest Jr., G. Hankey, S. Yusuf.
Homocyst( e)ine and cardiovascular disease: a critical review of the epidemiological evidence.
Ann Intern Med, 131 (1999), pp. 363-375
[6.]
J. Aranceta, L. Serra-Majem, C. Pérez-Rodrigo, J. Llopis, J. Matoix, L. Ribas, et al.
Vitamins in spanish food patterns: the eVe study.
Public Health Nutr, 4 (2001), pp. 1317-1323
[7.]
M. Klerk, P. Verhoef, R. Clarke, H.J. Blom, F.J. Kok, E.G. Schouten.
Mthfr C77CT polymorphism and risk of coronary heart disease: a meta-analysis.
Jama, 288 (2002), pp. 2023-2031
[8.]
B.G. Nedrebo, O. Nygard, P.M. Ueland, E.A. Lien.
Plasma total homocysteine in hyper– and hypothyroid patients during 12 months of treatment.
Clin Chem, 47 (2001), pp. 1738-1741
[9.]
J. Joven, R. Arcelús, J. Camps, J. Ordóñez-Llanos, E. Vilella, F. González-Sastre, et al.
Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome.
J Mol Med, 78 (2000), pp. 147-154
[10.]
D.W. Jacobsen.
Acquired hyperhomocysteinemia in heart transplant recipients.
Clin Chem, 44 (1998), pp. 2238-2239
[11.]
N. Ferré, F. Gómez, J. Camps, J.M. Simó, M.M. Murphy, J. Fernández-Baelart, et al.
Plasma homocysteine concentrations in patients with liver cirrhosis.
Clin Chem, 48 (2002), pp. 183-185
[12.]
E.L. López-Quesada, M.A. Vilaseca, S. González.
Homocisteína y gestación.
Med Clin (Barc, 115 (2000), pp. 352-356
[13.]
M.R.C. vitamin study group.
Prevention of neural tube defects: results of the medical research council vitamin study.
Lancet, 338 (1991), pp. 131-136
[14.]
P.F. Jacques, J. Selhub, A.G. Bostom, P.W.F. Wilson, I.H. Rosenberg.
The effect of folic acid fortification on plasma folate and total homocysteine concentrations.
N Engl J Med, 340 (1999), pp. 1449-1454
[15.]
M.G.A.J. Wouters, G.H.J. Boers, H.J. Bloom.
Hyperhomocysteinemia: a risk factor in women with unexplained recurrent pregnancy loss.
Fertil Steril, 60 (1993), pp. 820-824
[16.]
H. Refsum, P.E. Ueland.
Recent data are not in conflict with homocysteine as a cardiovascular risk factor.
Curr Opin Lipidol, 9 (1998), pp. 533-539
[17.]
Homocysteine studies collaboration. Homocysteinerisk of ischemic heart diseasestroke:meta-analysis.
Jama, 288 (2002), pp. 2015-2022
[18.]
M. Acevedo, G.L. Pearce, K. Kottke-Marchant, D.L. Sprecher.
Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients form a high-risk preventive cardiology clinic.
Arterioscler Thromb Vasc Biol, 22 (2002), pp. 1042-1045
[19.]
S. Yap, G.H.J. Boers, B. Wilcken, D.E. Wicklen, D.P. Brenton, P.J. Lee, et al.
Vascular outcome in patients with homocystinuria due to cystathionine beta-sinthase deficiency treated chronically. A multicenter observational study.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 2080-2085
[20.]
F. Nappo, N. De Rosa, R. Marfella, D. De Lucia, D. Ingiosso, A.F. Perna, et al.
Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins.
Jama, 281 (1999), pp. 2113-2118
[21.]
M.A. Hofmann, E. Lalla, Y. Lu, M.R. Gleason, B.M. Wolf, N. Tanfi, et al.
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.
J Clin Invest, 107 (2001), pp. 675-683
[22.]
E.B. Rimm, W.C. Willett, F.B. Hu, L. Sampson, G.A. Colditz, J.E. Manson, et al.
Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women.
Jama, 279 (1998), pp. 359-364
[23.]
D.G. Hackam, J.C. Peterson, J.D. Spence.
What level of plasma homocyst( e)inemia should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst( e)ine levels above and below 14 emol/l.
Am J Hypertens, 13 (2000), pp. 105-110
[24.]
S.C. De Jong, C.D.A. Stehouwer, M. van de Berg, T.W. Geurts, L.M. Bouter, J.A. Rauwerda.
Normohomocysteinemia and vitamin-treated hyperhomocysteinemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study.
J Intern Med, 246 (1999), pp. 87-96
[25.]
L.M. Taylor, G.L. Moneta, G.J. Sexton, R.A. Schuff, J.M. Porter.
Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease.
J Vasc Surg, 29 (1999), pp. 8-21
[26.]
J. Vermeulen, C.D.A. Stehouwer, J.W.R. Twisk, J. Van Der Berg, S.C. De Jong, A.J. Mackaay, et al.
Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.
Lancet, 355 (2000), pp. 517-522
[27.]
G. Schnyder, M. Roofi, R. Pin, Y. Flammer, G.T. Lange, F.R. Eberli, et al.
Decreased rate of coronary atherosclerosis after lowering of plasma homocysteine levels.
N Engl J Med, 345 (2001), pp. 1593-1600
[28.]
R.A.J.M. Van Dijk, J.A. Rauwerda, M. Steyn, J.W.R. Twisk, C.D.A. Stehouwer.
Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness. A 2-year, randomized, placebocontrolled trial.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 2072-20729
[29.]
S.N. Doshi, S.J. Moat, I.F.W. McDowell, M.J. Lewis, J. Goodfellow.
Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?.
Atherosclerosis, 165 (2002), pp. 1-3
[30.]
J. Loscalzo.
Homocysteine and dementias.
N Engl J Med, 346 (2002), pp. 466-468
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.